<DOC>
	<DOCNO>NCT01082796</DOCNO>
	<brief_summary>Diabetes mellitus grow global disease future , China , 1.2 million people per year diagnose diabetes mellitus . 90 % diabetes mellitus patient Type 2 diabetes mellitus . Glipizide potent drug service patient suffer Type 2 disease . Little information present relationship CYP2C19 genetic polymorphism glipizide , since recently investigator report existed tendency . In study investigator find CYP2C19 polymorphism significantly influence pharmacokinetics glipizide .</brief_summary>
	<brief_title>Cytochrome P450 2C19 Variant Related Pharmacokinetics Glipizide Extended Release Tablet Chinese Subjects</brief_title>
	<detailed_description>Blood sample obtain 127 unrelated healthy male Chinese subject Gansu Province . After genotyping , 14 subject ( age , 19-26 ; weight , 59.5-70.0 kg ) enrol study . They divide two group , EMs homo PMs group . There significant difference age body weight see two group . Each subject receive 5 mg glipizide extend release tablet daily 7 day . For first 6 day , glipizide administer standard breakfast . On day 7 , overnight fast , subject receive glipizide extend release tablet ( Glucotrol XL , Pfizer , USA ) 100 mL water . Standard meal give 4 h 10 h dosing . Venous blood sample collect immediately 2 , 4 , 6 , 8 , 10 , 12 , 14 , 16 , 20 , 24 , 36 , 48 h dosing . Blood sample , collect EDTA tube , centrifuge ( 2500 g ) immediately 10 min plasma sample separate store -80ÂºC assay . For safety , blood glucose level determine directly use Glucose Meter ( Accu-Chek , Roche , Germany ) 0 , 2 , 4 , 6 , 8 , 10 , 12 , 14 , 16 , 20and 24 h last dosing ( day 7 ) .</detailed_description>
	<mesh_term>Glipizide</mesh_term>
	<criteria>male healthy nonsmoker BMI &gt; 24 BMI &lt; 19 family history diabetes mellitus</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>